Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — H.C. Wainwright 23rd Annual Global Investment Conference 2021
26 slides from Collplant Biotechnologies's conference presentation, Sep 13, 2021
Slide 1: CollPlant Overview
CollPlant Overview H.C. Wainwright 23 rd Annual Global Investment Conference Se p t ember 2021
Slide 2: Safe harbor statement
Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimate
Slide 3: Unlocking the Regenerative Potential of rhCollagen
3 CollPlant – Unlocking the Regenerative Potential of rhCollagen Collaboration Agreements with Industry Leaders • AbbVie (ABBV) - Worldwide exclusive agreement for dermal and soft tissue fillers. Up to $103mm in payments plus royalties. • 3 D S ystems ( DDD ) - Bioprinted solutions for breast recons
Slide 4: Our body is made of collagen
Our body is made of collagen ~30% of body’s protein content Main structural protein in the extracellular matrix (e.g. cartilage, bones, tendons, ligaments, skin and vasculature) Ideal scaffolding molecule for regenerative medicine
Slide 5: Expressing human genes in transgenic tobacco plants
5 Expressing 5 human genes Transgenic tobacco plants
Slide 6: Plant-based platform produces human collagen at mass scale
Medical ae s t he t i c s Bi o I n k Commercial products (EU) rhCollagen production process Products rhCollagen G r owi n g Extraction Purification T r ans g e n i c t o b ac c o Cr ude e xt r act Plant - based platform produces human collagen in mass - scale
Slide 7: rhCollagen: clear advantages over tissue-extracted collagen
Better bio - functionality ● Accelerates human cell proliferation ● Faster tissue healing Superior homogeneity ● Controlled physical/rheological properties ● Reproducibility ● Transparency (not visible) Improved safety and greater purity ● Non - immunogenic ● Non - allergenic ● No pathogens ● No for
Slide 8: Product Pipeline
Product Pipeline Aesthetic medicine 3D bioprinting Dermal/soft tissue fillers BioInk formulations P h o t o c u ra b le dermal filler I n je ctab l e b reast implants Soft and hard tissues C ol l a b o ra t i o n with 3D bioprinted products Breast implants Regenerative Tissue Matrix for breast recon
Slide 9: Collagen platform drives diverse opportunities for value creation
9 Collagen platform drives diverse opportunities for value creation Organs & Tissues • Breast im p la n ts* • P h o t o c u ra b le fillers Regenerative and aesthetic medicine applications 3D models for drug discovery and tissue testing Development mode Value creation Co - developed Internally - dev
Slide 10: Dermal/Soft Tissue Fillers
Dermal/Soft Tissue Fillers
Slide 11: Dermal fillers market overview
Dermal fillers market overview ~2.2 M HA procedures in 2019 in the US 1 >$6.2B, 7.6% CAGR Global dermal filler market, 2019 2 CAGR 2020 - 2026 2 $100 - $250/unit Cost per syringe 3 11 1. 2. 3. https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic - surgery - statistics - full - repor
Slide 12: Collaboration agreement with AbbVie
12 Collaboration agreement with AbbVie (Feb. 2021) Agreement highlights: A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market Financial highlights: Up to $103M in potential payments, including: • $1 4 M u p f r on t p
Slide 13: Photocurable regenerative dermal filler key attributes
rhCollagen - based photocurable regenerative dermal filler key attributes I n jec t ion Sculpting Photocuring in - situ Tissue regeneration http://collplant.com/products/photocurable - dermal - filler - animation - video/ Good tissue retention Sculpting before curing Easy injection (30G needle) Opti
Slide 14: Injectable breast implants
Injectable breast implants* 14 • Composed of rhCollagen, additional materials and fat cells taken from the patient • Intended to promote breast tissue regeneration • Designed to support the viability and function of the autologous fat cells, and to attract cells to promote tissue regeneration • The
Slide 15: 3D Bioprinted Tissues and Organs
3D Bioprinted Tissues and Organs
Slide 16: A great medical need for supply of life saving organs
16 A great medical need for supply of life saving organs ~30,000 US transplants per year 115,000 US waiting list 900,000 US deaths per year from organ impairment 3D bioprinting expected to bridge this gap and allow unlimited supply of life saving organs The technological building blocks already exis
Slide 17: 3D bioprinting represents a wide range of development opportunities
17 In - house D e v e lopme n t Co llabo r at ion with tier - 1 De vel op m ent c os t Time to market Tiss u e s ● Br e a s t ● H e art valve ● C o r n e a ● S k i n ● Cart i l a g e En d ocr ine gl a n d s ● Ovary ● Pancreas ● Thyroid Organs ● Lungs ● K idne y ● Liver ● Heart Scaffolds ● Spine fusi
Slide 18: rhCollagen BioInk compositions in development
rhCollagen BioInk compositions in development Direct Ink Writing (DIW) I n k j e t Projection S t e r eol i t ho g r ap h y Laser Induced Forward Transfer (LIFT) Polymers (p hy si c al p r o p erties) Ceramics (h a r d tissue) Nanoparticles ( s u s t ai n ed r elease/ p hy si c al p r o p ertie s (
Slide 19: Breast Reconstruction / Augmentation
Breast Reconstruction / Augmentation
Slide 20: Regenerative Tissue Matrix for breast reconstruction
Provide extra coverage, direct - to - implant reconstruction and su p erior c o s m e t ic resu l ts U S : m o s t ly hu man - sourced (93%) EU : m o s t ly a n imal - sourced Used in 61% of U.S. breast reconstruction surgeries Breast reconstruction procedures using ADMS /yr (US): 60K Market p o t e
Slide 21: Breast implants market overview
Breast implants market overview Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it. $1.4B Market w o rl d wi d e (2018 ) 1 $ 5 - 10K Cost per full procedure in US 2 ~2,500,0
Slide 22: CollPlant's 3D bioprinted breast implants
* ECM - extracellular matrix 22 CollPlant’s 3D bioprinted breast implants Breast scaffold bioprinting ECM* components + autologous fat cells loading Impla n t a tion a n d vascularization Implant replacement by newly formed tissue
Slide 23: Product pipeline
23 Product pipeline Product Dermal filler (AbbVie) rhCollagen BioInks Regenerative Tissue Matrix (with DDD) Photocurable dermal filler Injectable breast implant Breast implants (3D printed) Next milestone According to plan 1 st BioInk market launch expected Q4, 2021 Preclinical package Preclinical p
Slide 24: Experienced management team
Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (N AS D AQ) & G am ida E&Y Ilana Belzer, PhD COO BioHarvest P roco g n i a L t d. O m ri x B ioph a r m a ceu t ic a l s Interpharm Nadav Orr, PhD
Slide 25: CollPlant investment thesis
CollPlant investment thesis Only commercially viable technology currently available that can produce truly human collagen Multi - billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics Broadly applicable technology: Ideal building block/scaffo
Slide 26: Thank you
Piowering G CollPlant ees Thank you
CollPlant Biotechnologies — H.C. Wainwright 23rd Annual Global Investment Conference 2021 on 6ix